Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Atlantic releases op-ed on Indian Americans and COVID-19

On April 15, Gargi Shindé, a 43-year-old nonprofit executive, logged onto Zoom at 5 a.m. From her home in Charlotte, North Carolina, she watched her relatives huddle around a bright-yellow body bag at a crematorium in Pune, India. They were performing the final rites for Shindé’s aunt, Vijaya, who had just died from COVID-19. All she could do was watch. The bag was almost fully zipped, revealing only Vijaya’s face, which appeared tiny and blurry through Shindé’s phone. “The only contribution I had was writing an obituary,” she told me, “and I’m scared I’ll have to do another one soon.”

On top of the grief and anger she’s feeling, Shindé has been struggling to comprehend the “surreal, stark contrast” between her own safety in Charlotte—where restrictions are loosening—and the catastrophe upending life back home. Then, on Thursday, Shindé emailed to tell me that another one of her aunts had just died from COVID-19.

Over the past two weeks, tragedies like what Shindé experienced are becoming a horrific new reality for Indian Americans. Many are glued to WhatsApp through the night, checking in on relatives as India confronts one of the world’s worst coronavirus surges. Every day, India is breaking grim global pandemic records, and even these numbers may be dramatically lower than the actual toll. The situation has become so dire that it verges on apocalyptic: Hospitals are running out of beds and oxygen, and people are dying while waiting for treatment. Crematoria are so overcrowded that workers are building makeshift funeral pyres in car parks, where grieving families wait for up to 20 hours for access.

Source: Atlantic

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!